Skip to content
The Great News – Lifestyle
Home
Sample Page
Author:
Biosplice Therapeutics, Inc.
Biosplice Executives to Appear on Health Uncensored with Dr. Drew on Sunday, November 1
October 29, 2026
European Medicines Agency Validates Biosplice’s Application for Lorecivivint (LOR) in Knee Osteoarthritis and Begins Review
October 2, 2026
Lorecivivint for Knee OA: UK MHRA Accepts Biosplice Application
September 8, 2026